Company Directory / Biotechnology Research
Public · NASDAQ:UMRXFor profitBiotechnology ResearchWaltham, Massachusetts, United States
Cogent Biosciences
Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.
- Founded
- 2014 12 years ago
- Staff
- 101-250 228 on LinkedIn
- Followers
- 13k on LinkedIn
- Funding
- $918M as listed, USD
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors… Read all
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has already exhibited promising early clinical activity and safety in a Phase 1/2 trial in patients with advanced GIST and also has the potential to fill an unmet need for patients living with Systemic Mastocytosis.
Set against six million companies
Size
101-250 people: larger than 85% of companies with a size listed. 228 people list it on LinkedIn.
Age
12 years old.
Reach
Website ranked #3,108,429 in the world for traffic, about 5k visits a month. 13,091 followers on LinkedIn.
What it does
BiotechnologyHealth CareMedicalTherapeuticsgastrointestinal stromal tumors (GIST)OncologySystemic Mastocytosiskinase inhibitors
Funding, as listed
$918M raised in total
- Rounds10
- LatestPost ipo equity, Feb 2024
- Latest amountUSD 50,000,000
- Investors30, 6 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Cogent Biosciences, field by field. Contact details are held but never shown.
The company
- Name
- Cogent Biosciences
- Type
- For profit
- Status
- Public · NASDAQ:UMRX
- Founded
- 2014
- Founders
- Dario Campana
- Industry
- Biotechnology Research
- Categories
- Biotechnology, Health Care, Medical, Therapeutics
- Specialities
- gastrointestinal stromal tumors (GIST), Oncology, Systemic Mastocytosis, kinase inhibitors
Where
- City
- Waltham
- Region
- Massachusetts
- Country
- United States
- Markets
- Greater Boston Area, East Coast, New England, Northeastern US
Size and reach
- Staff band
- 101-250
- People on LinkedIn
- 228
- LinkedIn followers
- 13,091
- Web traffic rank
- #3,108,429
- Monthly web visits
- 4,938
Funding, as listed
- Total
- $917,700,000 USD
- Rounds
- 10
- Latest round
- Post ipo equity
- Latest round date
- Feb 2024
- Latest amount
- 50,000,000 USD
- Investors
- 30
- Lead investors
- 6
- Stock listing
- NASDAQ:UMRX
- Listing status
- public
Corporate family
- Acquisitions made
- 1
About this record
- Sources
- Crunchbase, LinkedIn
- Last imported
- Sept 2026
Growth, as the source summarises it
Cogent Biosciences may be growing as evidenced by recent financial and operational developments. The company has reported a positive position to deliver on growth plans, indicating a solid foundation for future expansion. Additionally, a significant investment by Capstone Investment Advisors LLC, which purchased shares of the company, suggests confidence in Cogent Biosciences' potential for growth. Furthermore, the appointment of a new Chief Commercial Officer could be indicative of the company's focus on commercial strategy and market presence, which is often a precursor to growth in the biotechnology sector.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Biotechnology Research in United States.
Global Blood TherapeuticsSouth San Francisco · 251-500 people · 23k followers
Editas MedicineCambridge · 251-500 people · 49k followers
CueSan Diego · 1001-5000 people · 23k followers
Recursion PharmaceuticalsSalt Lake City · 501-1000 people · 65k followers
Apeel SciencesGoleta · 101-250 people · 37k followersFrom the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.